Author

M. Hemann

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Assay:CRISPR screen· 1 Approach:experimental assay· 1 Approach:genetic perturbation / CRISPR· 1 Organism:mouse· 1

Frequent Co-Authors

A. Ramos· 1 shared A. Regev· 1 shared C. E. Koch· 1 shared D. A. Lauffenburger· 1 shared D. Goulet· 1 shared J. Froese· 1 shared J. G. Doench· 1 shared K. L. Abbott· 1 shared

Activity by Year

2021-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Ramos

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Leukemia-intrinsic determinants of CAR-T response revealed by iterative in vivo genome-wide CRISPR screening.

A. Ramos, C. E. Koch, Y. Liu, R. D. Hellinger, T. Kyung, K. L. Abbott, J. Froese, D. Goulet, K. S. Gordon, R. C. Larson, J. G. Doench, A. Regev, M. G. Vander Heiden, M. V. Maus, M. E. Birnbaum, M. Hemann

This study identifies leukemia-intrinsic resistance mechanisms to CAR-T therapy through in vivo CRISPR screening in a murine B-ALL model, revealing IFNγ/JAK/STAT and antigen processing pathways as key mediators.

bioRxiv · Feb 15, 2022 · PreprintCancer Biology

Collateral Responses to Classical Cytotoxic Chemotherapies are Heterogeneous and Sensitivities are Sparse

S. Dalin, D. A. Lauffenburger, M. Hemann

The paper examines collateral responses to four classical chemotherapy agents and finds no collateral sensitivities but observes phenotypic heterogeneity unrelated to transcriptomic heterogeneity.

bioRxiv · Apr 15, 2021Cancer Biology